Ionis Pharmaceuticals, Inc. (IONS) 은(는) 상장 기업입니다 헬스케어 섹터의 바이오 산업에서 운영. 본사 소재지는 Carlsbad, CA, 미국. 현재 CEO는 Brett Monia.
IONS 을(를) 보유 IPO 날짜 1991-05-17, 1,069 명의 정규직 직원, 에 상장 NASDAQ Global Select, 시가총액 $12.68B.
Ionis Pharmaceuticals, Inc. is a biopharmaceutical company based in Carlsbad, California, specializing in the discovery and development of RNA-targeted therapeutics. The company markets approved treatments including SPINRAZA for spinal muscular atrophy, TEGSEDI for hereditary transthyretin-mediated amyloidosis, and WAYLIVRA for familial lipid disorders, while maintaining a robust pipeline of Phase 3 candidates targeting rare genetic diseases, cardiovascular conditions, and neurological disorders. Through strategic collaborations with major pharmaceutical partners including Biogen, AstraZeneca, Bayer, GlaxoSmithKline, Novartis, and Roche, Ionis is advancing its platform across metabolic diseases, infectious diseases, renal diseases, and oncology.
